These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
736 related articles for article (PubMed ID: 19817610)
21. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. Kim SY; Sweet S; Slichter D; Goldie SJ BMC Public Health; 2010 May; 10():253. PubMed ID: 20470426 [TBL] [Abstract][Full Text] [Related]
22. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis. Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424 [TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness of rotavirus vaccination in Armenia. Jit M; Yuzbashyan R; Sahakyan G; Avagyan T; Mosina L Vaccine; 2011 Nov; 29(48):9104-11. PubMed ID: 21945959 [TBL] [Abstract][Full Text] [Related]
24. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand. Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220 [TBL] [Abstract][Full Text] [Related]
25. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Goldie SJ; Diaz M; Constenla D; Alvis N; Andrus JK; Kim SY Vaccine; 2008 Aug; 26 Suppl 11():L59-72. PubMed ID: 18945403 [TBL] [Abstract][Full Text] [Related]
26. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria. Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Sinha A; Levine O; Knoll MD; Muhib F; Lieu TA Lancet; 2007 Feb; 369(9559):389-96. PubMed ID: 17276779 [TBL] [Abstract][Full Text] [Related]
28. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda. Tate JE; Kisakye A; Mugyenyi P; Kizza D; Odiit A; Braka F Vaccine; 2011 Apr; 29(17):3329-34. PubMed ID: 21241733 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of rotavirus vaccination in Argentina. Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152 [TBL] [Abstract][Full Text] [Related]
30. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026 [TBL] [Abstract][Full Text] [Related]
31. Economic evaluation of a routine rotavirus vaccination programme in Indonesia. Wilopo SA; Kilgore P; Kosen S; Soenarto Y; Aminah S; Cahyono A; Ulfa M; Tholib A Vaccine; 2009 Nov; 27 Suppl 5():F67-74. PubMed ID: 19931723 [TBL] [Abstract][Full Text] [Related]
32. Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Melliez H; Levybruhl D; Boelle PY; Dervaux B; Baron S; Yazdanpanah Y Vaccine; 2008 Jan; 26(5):706-15. PubMed ID: 18166250 [TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of Haemophilus influenzae type B vaccination in Indonesia: a cost-effectiveness analysis. Broughton EI J Public Health (Oxf); 2007 Dec; 29(4):441-8. PubMed ID: 17875589 [TBL] [Abstract][Full Text] [Related]
34. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi. Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006 [TBL] [Abstract][Full Text] [Related]
35. Rotavirus disease in Uzbekistan: cost-effectiveness of a new vaccine. Isakbaeva ET; Musabaev E; Antil L; Rheingans R; Juraev R; Glass RI; Bresee JS Vaccine; 2007 Jan; 25(2):373-80. PubMed ID: 16930784 [TBL] [Abstract][Full Text] [Related]
36. Potential epidemiological and economical impact of two rotavirus vaccines in Colombia. De la Hoz F; Alvis N; Narváez J; Cediel N; Gamboa O; Velandia M Vaccine; 2010 May; 28(22):3856-64. PubMed ID: 20347057 [TBL] [Abstract][Full Text] [Related]
37. Assessing the effectiveness and public health impact of rotavirus vaccines after introduction in immunization programs. Patel MM; Parashar UD J Infect Dis; 2009 Nov; 200 Suppl 1():S291-9. PubMed ID: 19817612 [TBL] [Abstract][Full Text] [Related]
39. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Cook J; Jeuland M; Whittington D; Poulos C; Clemens J; Sur D; Anh DD; Agtini M; Bhutta Z; Vaccine; 2008 Nov; 26(50):6305-16. PubMed ID: 18835415 [TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model. Patel HD; Roberts ET; Constenla DO Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]